Electromed, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures, and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, principally the SmartVest Airway Clearance System. Its markets include U.S. home care, institutional customers, home-care distributors, and international distributors. This unaudited quarterly report covers the three months ended September 30, 2019, the first quarter of fiscal 2020, compared with the three months ended September 30, 2018.
Financial Performance and Position
| Metric | Q1 FY2020 | Q1 FY2019 | Change |
|---|---|---|---|
| Net revenue | $8.302 million | $7.276 million | 14.1% |
| Gross profit | $6.342 million | $5.543 million | 14.4% |
| Gross margin | 76.4% | 76.2% | Up 0.2 percentage points |
| Operating income | $1.349 million | $0.202 million | Increase of $1.147 million |
| Operating margin | 16.2% | 2.8% | Up 13.4 percentage points |
| Net income | $1.015 million | $0.157 million | Increase of $0.857 million |
| Net margin | 12.2% | 2.2% | Up 10.0 percentage points |
| Diluted EPS | $0.12 | $0.02 | Increase of $0.10 |
| Operating cash flow | $0.629 million | $0.303 million | Increase of $0.326 million |
Revenue growth was led by home care revenue of $7.492 million, up 11.4%, and institutional revenue of $625,000, up 49.2%. Home-care distributor revenue contributed $120,000 in the current period, while international revenue declined 51.2% to $66,000. Home-care revenue benefited from a higher average allowable, improved referral-to-approval rates, and more referrals per field sales employee.
Cash increased to $8.035 million at September 30, 2019 from $7.808 million at June 30, 2019. Working capital was approximately $21.757 million. Total assets were $30.303 million, total liabilities were $3.332 million, and shareholders’ equity was $26.972 million.
Investing cash outflows were $415,000, including $405,000 for property and equipment and $11,000 for finite-life intangible assets. Financing cash inflows were $13,000 from stock-option exercises. The company reported no outstanding balance on its $2.5 million revolving credit facility and stated that the full $2.5 million was available at quarter-end.
Material Changes Versus the Prior Comparable Period
- Revenue increased 14.1%, primarily because of higher home-care and institutional sales and the launch of home-care distributor sales.
- Gross margin improved modestly to 76.4%, principally due to payer mix and a higher average allowable.
- Selling, general, and administrative expense decreased 7.2% to approximately $4.895 million, driven by lower headcount, share-based compensation, and sales incentives.
- Payroll and compensation-related expense declined 7.9%, although management expects these costs to rise as the direct sales force is expanded.
- Research and development expense increased to approximately $99,000 from $68,000.
- Net income increased more than sixfold, reflecting higher revenue and lower payroll and compensation-related costs.
- Capital expenditures increased substantially from $10,000 to approximately $405,000. The company completed a New Prague facility expansion in September 2019 at a total cost of approximately $1.5 million.
- The company adopted ASC 842, Leases, effective July 1, 2019, recognizing approximately $138,000 of right-of-use assets and operating lease liabilities at September 30, 2019.
Outlook, Commentary, Risks, and Unusual Items
Management believes existing working capital and available credit will provide adequate liquidity for the next year. It expects payroll and compensation costs to increase as direct sales staffing expands and expects research and development spending to rise to approximately 2%–4% of revenue for the remainder of the fiscal year to support development of a next-generation device.
The facility expansion is expected to save more than $130,000 in annual lease expense and provide infrastructure for long-term growth. Management expects planned equipment purchases to be funded through operating cash flow or the credit facility.
The revolving credit facility expires on December 18, 2019, if not renewed. It is secured by substantially all tangible and intangible assets and includes a minimum tangible net worth covenant of $10.125 million and restrictions on additional indebtedness and dividends. The company was in compliance at quarter-end, but failure to comply or failure to renew could restrict liquidity and permit acceleration or foreclosure remedies.
Key business risks include changes to Medicare, Medicaid, and private-insurance reimbursement; competition; regulatory compliance and approvals; development of new distribution channels; protection of intellectual property; international-market volatility; and the ability to renew or replace credit facilities. Revenue estimates include variable consideration related to payer approvals, appeals, deductibles, insurance status, and installment payments, creating estimation and potential revenue-reversal risk. The filing reports an $800,000 warranty reserve and no material undisclosed litigation.
Investor Verification Checklist
- Verify the sustainability of the 14.1% revenue growth, particularly home-care payer mix, referral conversion, and distributor-channel contribution.
- Assess whether the improved operating margin can be maintained as sales hiring and R&D spending increase.
- Confirm renewal or replacement of the $2.5 million revolving credit facility before its December 18, 2019 expiration.
- Evaluate payer reimbursement policies and the collectability of $12.719 million of receivables and $1.008 million of contract assets.
- Review the return on the approximately $1.5 million facility expansion and the expected lease-cost savings.
- Monitor warranty claims, inventory obsolescence, and estimates of variable consideration.
- Consider the dilution and expense impact of 806,350 outstanding stock options and ongoing share-based compensation.